Arch Venture Management’s Beam Therapeutics BEAM Stock Holding History

Arch Venture Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$156M	Hold	4,540,132	–	–	14.16%	2
2026 Q1	$108M	Hold	4,540,132	–	–	15.98%	5
2025 Q4	$126M	Hold	4,540,132	–	–	19.31%	2
2025 Q3	$110M	Hold	4,540,132	–	–	22.38%	2
2025 Q2	$77.2M	Hold	4,540,132	–	–	25.82%	1
2025 Q1	$88.7M	Hold	4,540,132	–	–	43%	1
2024 Q4	$113M	Sell	4,540,132 -294,521	-6%	-$7.52M	48.91%	1
2024 Q3	$118M	Sell	4,834,653 -608,386	-11%	-$15.7M	45.46%	1
2024 Q2	$128M	Buy	+5,443,039	New	+$134M	47.94%	1

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arch Venture Management's BEAM Position: Q2 2026 in Review

Arch Venture Management held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 4,540,132 shares worth $156M. The position accounts for 14.16% of the portfolio, ranked #2.

Arch Venture Management first reported a position in BEAM in Q2 2024 and has held it in 9 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Arch Venture Management held 4,540,132 shares of Beam Therapeutics worth $156M as of Q2 2026.
Arch Venture Management left its Beam Therapeutics share count unchanged in Q2 2026.
Beam Therapeutics made up 14.16% of Arch Venture Management's portfolio in Q2 2026, its #2 holding.
Arch Venture Management first reported a position in Beam Therapeutics in Q2 2024 and has held it in 9 quarters since.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.